Study guide
19.1 KRIs, Acceptable Ranges and Trial-Level Quality
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
19.1 KRIs, Acceptable Ranges and Trial-Level Quality
Key Takeaways Explain This Topic AI
Risk indicators need context, defined denominators and proportionate follow-up.
Trial-level acceptable ranges help identify potentially systematic issues.
Important quality issues and remedial actions should be evaluated and documented in reporting.
Last updated: October 2026
KRIs, Acceptable Ranges and Trial-Level Quality
Adverse Event (AE) Underreporting:
Metric: Reported events per participant over a defined comparable exposure period; use person-time when exposure differs.
Operational Red Flag: Across 80 trial sites evaluating a novel cytotoxic therapeutic, the illustrative study-wide average is 4.2 AEs per subject over a comparable exposure period . Site 112, which has enrolled 18 subjects over 6 months, reports zero adverse events .
CRA Operational Interpretation: In an aggressive pharmacological study, reporting zero adverse events does not mean the site provides superior clinical care; it warrants prompt investigation for possible underreporting, absent investigator inquiry, failure to review concurrent medications, or lack of source data transcription. A proportionate follow-up, potentially an on-site visit, is warranted to execute comprehensive Source Data Review (SDR) across medical progress notes and nursing logs.
Concomitant Medication Underreporting:
Metric: Number of reported concomitant medications per participant.
Operational Red Flag: A geriatric patient with advanced diabetes and chronic kidney disease has zero concomitant medications recorded in the eCRF.
CRA Operational Interpretation: It may be unexpected for a multimorbid geriatric patient to receive no concomitant prescriptions, over-the-counter drugs, or nutritional supplements. The CRA must cross-reference pharmacy dispensing histories and primary care physician notes.
Protocol Deviation Velocity & Query Latency:
Metric: Rate of new protocol deviations per subject visit and median calendar days to resolve open EDC data queries.
Operational Red Flag: A site's query resolution latency exceeds 45 days (study benchmark is fewer than 5 days), accompanied by a high density of visit window deviations.
CRA Operational Interpretation: Indicates severe site staff turnover, lack of coordinator availability, or inadequate investigator oversight.
Quality Tolerance Limits (QTLs): Study-Level Risk Governance
A useful operational distinction is the difference between Key Risk Indicators (KRIs) and Quality Tolerance Limits (QTLs) :
Key Risk Indicators (KRIs): Often evaluated at the site level to identify individual outlier centers requiring targeted CRA visits, retraining, or corrective actions.
Quality Tolerance Limits (QTLs): Evaluated at the trial level across the entire clinical study. QTLs represent predefined statistical boundaries that consider the medical and statistical characteristics of the trial design. They are designed to identify systematic issues that could compromise trial integrity or subject safety across the entire program.
Illustrative Trial-Level Ranges
These are hypothetical examples for understanding a metric; they are not ICH-prescribed limits or default acceptable rates. Each trial must justify its own ranges:
Study Dropout / Lost-to-Follow-up Rate: Predefined QTL set at >15% overall participant withdrawal rate prior to primary endpoint completion.
Primary Endpoint Missing Data: Predefined QTL set at >3% missing primary efficacy measurements across the study population.
Major Protocol Deviation Rate in Primary Population: Predefined QTL set at >5% of randomized subjects experiencing a major deviation affecting the per-protocol analysis set.
Evaluating deviations from predefined acceptable ranges
E6(R3) calls for evaluation when predefined acceptable ranges relevant to critical-to-quality factors are exceeded. Determine whether the observation reflects an important systematic issue or another explanation. Investigate causes and implement proportionate remedial action where appropriate; do not assume every threshold crossing automatically invalidates the study or requires a programme-wide CAPA.
Document important issues and remedial actions, including relevant quality-management information in the clinical study report. An ICH guideline is not a universal statute assigning one legal consequence to every alert. Apply actual reporting requirements and assess participant protection and reliable results. A site KRI may require targeted follow-up even when a trial-wide range has not been crossed, while an overall signal can reveal a design or system problem affecting several sites.
Reading risk metrics with the right denominator
An illustrative trial has 200 participants expected to contribute a primary assessment at a data cut, and 8 assessments are missing. The missing-assessment proportion is 8/200 × 100 = 4% . The figure answers a defined operational question; it does not establish a universal acceptable limit. A threshold should have been justified from the study's scientific and operational characteristics.
If a site reports 2 missing assessments among 10 expected, its site proportion is 20% . Comparing 2 missing records with the trial's 8 without denominators would conceal the higher local rate. Investigate timing, participant status, source availability and whether the data were truly expected. An apparent missing assessment can represent late transmission, a wrongly assigned visit or genuine noncollection.
A metric crossing a predefined acceptable range should prompt evaluation of its importance and proportionate action. It is not automatic proof that the trial's conclusions are invalid. Conversely, a trial-wide proportion below the range can hide a serious local problem affecting participant protection. Use site and trial perspectives together, document meaningful issues and response, and reassess controls as evidence accumulates.
Do not change a threshold retrospectively just to make an alert disappear without a justified, controlled evaluation.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E8(R1) .